Results 21 to 30 of about 12,210 (151)

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. [PDF]

PLoS ONE, 2015
To compare treatment patterns of intravitreal ranibizumab and aflibercept for the management of neovascular age-related macular degeneration (nAMD) in a real-world setting over the first 12 months of treatment.A proprietary clinical database was used to ...
Alberto Ferreira, Alexandros Sagkriotis, Melvin Olson, Jingsong Lu, Charles Makin, Fran Milnes   +5 more
doaj   +1 more source

Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia [PDF]

International Journal of Ophthalmology, 2017
AIM: To describe the prevalence and changes in treatment patterns of ranibizumab and photodynamic therapy (PDT) among retinal disease patients who attended the Ophthalmology Clinic in the tertiary care Hospital Selayang from 2010 to 2014. METHODS: Study
Nur Afiqah Mohamad, Vasudevan Ramachandran, Patimah Ismail, Hazlita Mohd Isa, Yoke Mun Chan, Nor Fariza Ngah, Norshakimah Md Bakri, Siew Mooi Ching, Fan Kee Hoo, Wan Aliaa Wan Sulaiman   +9 more
doaj   +1 more source

The results of comparative analysis of angiogenic and laser therapy for diabetic macular edema in diabetes type 2

Oftalʹmologiâ, 2014
Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.Methods: The progress of visual acuity, retinal thickness and light sensivity after laser ...
I. V. Vorobieva, E. V. Parfenova, D. A. Merkushenkova, P. I. Makarevich, V. I. Alekhnovich   +4 more
doaj   +3 more sources

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Ophthalmology and Therapy
Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani   +25 more
doaj   +1 more source

Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate if a standardized combination therapy regimen, utilizing 3 monthly ranibizumab injections followed by navigated laser photocoagulation, reduces the number of total ranibizumab injections required for treatment of diabetic macular ...
Raffael Liegl, Julian Langer, Florian Seidensticker, Lukas Reznicek, Christos Haritoglou, Michael W Ulbig, Aljoscha S Neubauer, Anselm Kampik, Marcus Kernt   +8 more
doaj   +1 more source

Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary

Interdisciplinary Medicine, EarlyView.
This review systematically summarizes the driving mechanisms of implantable on‐demand drug delivery systems (IDDS), including endogenous, exogenous, and closed‐loop strategies. It highlights the pivotal roles of flexible electronics and miniaturization in enhancing the tissue conformity and spatial adaptability.
Yu Zeng, Rongtai Su, Manyu Zhao, Xin Song, Ran Liu, Yuhao Zhou, Chaojuan Yang, Yanli Jiao, Xiao‐Wei Xiang, Lingqian Chang   +9 more
wiley   +1 more source

Non‐physician delivered intravitreal injection service: A systematic review of safety, implementation, training and patient experience

Acta Ophthalmologica, EarlyView.
Abstract The global demand for intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy continues to rise, straining ophthalmic capacity worldwide. Task shifting from physicians to trained non‐physician healthcare professionals has emerged as a potential strategy to expand service delivery.
Trang Truong Laursen, Haris Bralic, Jakob Grauslund, Yousif Subhi, Lonny Stokholm   +4 more
wiley   +1 more source

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology, 2013
AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model.METHODS:Sixteen corneas of 16 rats were chemically cauterized and ...
Cem Küçükerdönmez, Veysi Öner, Ebru Eren Akar, Yonca Aydın Akova   +3 more
doaj   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source